Like most websites, we use cookies and other similar technologies for a number of reasons, such as keeping our website reliable and secure, personalizing content, providing social media features and to better understand how our site is used. By using our site, you are agreeing to our use of these tools. Learn More

Your Location is set to:

CLEAR Outcomes


The purpose of this study is to determine if treatment with bempedoic acid( ETC-1002), versus a placebo decreases the risk of cardiovascular events in patients who are statin intolerant.  A placebo is made to look like the study drug but has no bempedoic acid.

Principal Investigator(s)
Richard Zelman, MD

Clinical Trial Categories

  • Outpatient Medications
  • Cardiovascular Disease
  • Coronary Disease
Kelcie Brown, RN at
How to Participate

For more information speak with your cardiologist,  primary care physician or contact our experienced research nurse:

                    Kelcie Brown, RN at 508-778-5900


  • Heart & Vascular Institute